caa a22 4500 606174834 CHVBK 20210128100740.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s00018-015-2019-7 doi (NATIONALLICENCE)springer-10.1007/s00018-015-2019-7 Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors? [Elektronische Daten] [Naomi van der Sligte, Kim Kampen, Eveline de Bont] The introduction of kinase inhibitors in cancer medicine has transformed chronic myeloid leukemia from a fatal disease into a leukemia subtype with a favorable prognosis by interfering with the constitutively active kinase BCR-ABL. This success story has resulted in the development of multiple kinase inhibitors. We are currently facing significant limitations in implementing these kinase inhibitors into the clinic for the treatment of pediatric malignancies. As many hallmarks of cancer are known to be regulated by intracellular protein signaling networks, we suggest focusing on these networks to improve the implementation of kinase inhibitors. This viewpoint will provide a short overview of currently used strategies for the implementation of kinase inhibitors as well as reasons why kinase inhibitors have unfortunately not yet been widely used for the treatment of pediatric cancers. We argue that by using a future personalized medicine strategy combining kinomics, proteomics, and drug screen approaches, the gap between pediatric cancers and the use of kinase inhibitors may be bridged. The Author(s), 2015 Targeted therapy nationallicence Kinomics nationallicence Proteomics nationallicence Drug screen approaches nationallicence Study strategies nationallicence van der Sligte Naomi Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700, Groningen, The Netherlands aut Kampen Kim Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700, Groningen, The Netherlands aut de Bont Eveline Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700, Groningen, The Netherlands aut Cellular and Molecular Life Sciences Springer Basel 72/19(2015-10-01), 3589-3598 1420-682X 72:19<3589 2015 72 18 https://doi.org/10.1007/s00018-015-2019-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00018-015-2019-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- van der Sligte Naomi Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Kampen Kim Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700, Groningen, The Netherlands aut NATIONALLICENCE 700 1- de Bont Eveline Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700, Groningen, The Netherlands aut NATIONALLICENCE 773 0- Cellular and Molecular Life Sciences Springer Basel 72/19(2015-10-01), 3589-3598 1420-682X 72:19<3589 2015 72 18